Psychedelic Alpha Bulletin 213: Compass speeds psilocybin launch planning, Australia funds veteran therapy, and AbbVie pays $900M upfront

Psilocybin therapy and related commercialization move on multiple fronts in Psychedelic Alpha Bulletin 213. Compass accelerates plans for a psilocybin launch, indicating faster timelines from development toward market readiness. In parallel, Australia’s Veterans Affairs funding supports psychedelic therapy for veterans, framing psychedelics as an emerging public-health or service-delivery pathway rather than only private clinical trials. The bulletin also highlights deal-driven momentum, with AbbVie paying a $900M upfront for a psychedelic candidate. Together, these items connect pipeline acceleration, government-backed access for specific populations, and large pharma capital commitments that can shape the pace and scale of upcoming trials and approvals.